Antengene Corporation Limited (HKG:6996)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 1.94B -39.9% |
| Revenue (ttm) | 652.54M +570.1% |
| Net Income | 61.87M |
| EPS | 0.10 |
| Shares Out | 687.51M |
| PE Ratio | 29.04 |
| Forward PE | 12.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 375,000 |
| Open | 2.945 |
| Previous Close | 2.820 |
| Day's Range | 2.700 - 2.945 |
| 52-Week Range | 2.620 - 6.280 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About Antengene Corporation
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f... [Read more]
Financial Performance
In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Antengene Doses First Patient In Pivotal Phase III ATG-022 Gastric Cancer Trial; Stock Up
(RTTNews) - Antengene Corporation Ltd. (6996.HK), a commercial-stage biotech company, announced Monday that the first patient has been dosed in China in the pivotal Phase III CLINCH-3 study evaluating...
Antengene Corporation Earnings release: H1 2026
Antengene Corporation released its H1 2026 earnings on August 21, 2026, summarizing the period's financial results.
Antengene Corporation Slides: H1 2026
Antengene Corporation has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 21, 2026.
Antengene Corporation Quarterly report: H1 2026
Antengene Corporation has published its H1 2026 quarterly earnings report on August 21, 2026.
Antengene Licenses ATG-106 And Grants Option Rights On Undisclosed Bispecific TCE To K2 Therapeutics
(RTTNews) - Antengene Corporation Limited (6996.HK), a commercial-stage biopharmaceutical company, announced that it has entered into an exclusive license agreement with K2 Therapeutics, a subsidiary ...
Antengene Corporation Earnings release: H2 2025
Antengene Corporation released its H2 2025 earnings on March 20, 2026, summarizing the period's financial results.
Antengene Corporation Slides: H2 2025
Antengene Corporation has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 20, 2026.
Antengene Corporation Annual report: H2 2025
Antengene Corporation has published its H2 2025 annual report on March 20, 2026.
Antengene Corporation Transcript: Status update
Announced a global licensing deal with UCB for ATG-201, securing $80 million upfront and up to $1.2 billion in milestones, with Antengene conducting initial phase I trials and UCB leading global development. The AnTenGager platform underpins a robust pipeline and supports future collaborations.
Antengene Corporation Press release: Status update
Antengene Corporation issued a press release on March 4, 2026, disclosing material business information to investors.
Antengene Corporation Slides: Status update
Antengene Corporation has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL
(RTTNews) - Antengene Corporation Limited (6996.HK) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO (selinexor...
Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022
(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLIN...